FBRX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -2.54%, SMA50 1.05%, SMA200 75.26%). The stock’s 14-day RSI is 49.41 (neutral), while the ATR of 2.8 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.86% below its high and over 497.14% above its low. Average 10-day trading volume of 1.05 million shares is significantly above the 3-month average of 400.49 thousand, indicating heightened recent market interest.

Forte Biosciences, Inc. has 12.43 million shares outstanding. The public float is 10.22 million shares, elevated short interest at 1.25% of float. This equals 128.75 thousand shares. The short ratio is 2.4 days. Institutional investors hold 89.92% of the float. Insiders own 4.96%. Oliveira Steven Michael holds 2.87 million shares, Wagner Paul A. has 1.82 million shares and Hasnain Faheem has 241.72 thousand shares.

Forte Biosciences, Inc. generated EPS of -$4.44 over the past year. Five-year average earnings growth is 24.08%. Wall Street analysts project EPS growth of 29.76% annually over the next five years. The latest quarter delivered EPS of -$1.24. The next quarter is forecast at -$1.18. Next year's EPS is expected at -$8.62. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $75.00 to $61.00. The high target offers 104.36% upside. The low target suggests 66.21% downside. The mean target is $65.50. This offers 78.47% upside. Forte Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 6.9%. The prior quarter beat by 2.11%. Over the last six quarters, Apple has recorded several small beats. These include -46.15% in March 24, 2025.

Forte Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.52. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Forte Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -19.02%, with price expected at $29.72 by July 23, 2026, within a range of $26.36 to $32.87 3-Month Outlook: Projected fall of -23.13%, reaching $28.21 by October 07, 2026, with a range of $25.80 to $30.35. 1-Year Outlook: Projected loss of -16.16%, with price at $30.77 by July 09, 2027, within a range of $27.96 to $33.10.

Forte Biosciences, Inc. (NASDAQ:FBRX) shares are up 11.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Forte Biosciences, Inc. trading at a premium to the broader market with a P/E of -7.8. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $49.27, suggesting 34.25% upside. Our AI forecast model points to short-term weakness (-19.02% over two weeks), a medium-term fall (-23.13% over three months), and a longer-term loss (-16.16% over one year), with expected trading ranges indicating moderate volatility.

Forte Biosciences, Inc. trades at a P/E ratio of -7.8, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 151.34 reflecting a rich premium to book value. The P/FCF stands at -8.35, also above market averages. Compared to sector medians, Forte Biosciences, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Forte Biosciences, Inc. (NASDAQ:FBRX) closed at $44.09 USD, gaining $7.39 (20.13%) from the previous close of $36.70. The stock is currently within 5% of its 52-week high $9.10 and $45.14. With a market capitalization of about $612.21 million, Forte Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.84). Key stats such as the average daily volume over the past year has been around 388.08 thousand shares, trading with heavier-than-usual volume. Headquartered in Dallas, TX, Forte Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul A. Wagner, the company employs approximately 22 people and listed since April 13, 2017. Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase.